{"entity":{"type":"insider","cik":"0001706863","url":"/insider/0001706863","json_url":"/insider/0001706863.json","name":"RAY DEBANJAN","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":21,"n_filings":18,"first":"2017-07-06","last":"2018-12-14","span_basis":"filed_date"},"name_variants":[{"name":"RAY DEBANJAN","source":"filing","n_filings":18,"first_seen":"2017-07-06","last_seen":"2018-12-14"}],"transactions":[{"id":6103339,"accession":"0001567619-18-008005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-18-008005","line_url":"/filing/0001567619-18-008005#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":45000.0,"total_display":"45,000.00","total_whole":"45,000","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-12","filed_date":"2018-12-14","scope":"insider"},{"id":6402716,"accession":"0001567619-18-005082","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-18-005082","line_url":"/filing/0001567619-18-005082#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":45000.0,"total_display":"45,000.00","total_whole":"45,000","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-01","filed_date":"2018-11-05","scope":"insider"},{"id":6739692,"accession":"0001567619-18-003477","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-18-003477","line_url":"/filing/0001567619-18-003477#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":18.46,"price_display":"18.46","price_state":"stated","total_value":55380.0,"total_display":"55,380.00","total_whole":"55,380","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-02","scope":"insider"},{"id":6880569,"accession":"0001567619-18-002232","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-18-002232","line_url":"/filing/0001567619-18-002232#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":22.39,"price_display":"22.39","price_state":"stated","total_value":67170.0,"total_display":"67,170.00","total_whole":"67,170","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-04","filed_date":"2018-09-06","scope":"insider"},{"id":6283718,"accession":"0001140361-18-035277","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-18-035277","line_url":"/filing/0001140361-18-035277#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":26.05,"price_display":"26.05","price_state":"stated","total_value":78150.0,"total_display":"78,150.00","total_whole":"78,150","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-01","filed_date":"2018-08-02","scope":"insider"},{"id":6310994,"accession":"0001140361-18-031328","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-18-031328","line_url":"/filing/0001140361-18-031328#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":22.56,"price_display":"22.56","price_state":"stated","total_value":67680.0,"total_display":"67,680.00","total_whole":"67,680","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-02","filed_date":"2018-07-03","scope":"insider"},{"id":6577348,"accession":"0001140361-18-027475","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-18-027475","line_url":"/filing/0001140361-18-027475#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":25.931,"price_display":"25.93","price_state":"stated","total_value":77793.0,"total_display":"77,793.00","total_whole":"77,793","shares_owned_after":5928.0,"shares_owned_after_display":"5,928","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-01","filed_date":"2018-06-05","scope":"insider"},{"id":6134803,"accession":"0001140361-18-021345","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-18-021345","line_url":"/filing/0001140361-18-021345#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":26.5207,"price_display":"26.52","price_state":"stated","total_value":79562.1,"total_display":"79,562.10","total_whole":"79,562","shares_owned_after":4741.0,"shares_owned_after_display":"4,741","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-01","filed_date":"2018-05-02","scope":"insider"},{"id":6511184,"accession":"0001140361-18-016993","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-18-016993","line_url":"/filing/0001140361-18-016993#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":28.12,"price_display":"28.12","price_state":"stated","total_value":84360.0,"total_display":"84,360.00","total_whole":"84,360","shares_owned_after":4741.0,"shares_owned_after_display":"4,741","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-02","filed_date":"2018-04-04","scope":"insider"},{"id":6310487,"accession":"0001140361-18-012009","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001140361-18-012009","line_url":"/filing/0001140361-18-012009","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":30.3726448,"price_display":"30.37","price_state":"stated","total_value":607452.896,"total_display":"607,452.90","total_whole":"607,453","shares_owned_after":6685.0,"shares_owned_after_display":"6,685","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-02","filed_date":"2018-03-05","scope":"insider","n_lines":3},{"id":6310476,"accession":"0001140361-18-012009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-18-012009","line_url":"/filing/0001140361-18-012009#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13000.0,"shares_display":"13,000","price_per_share":29.4032,"price_display":"29.40","price_state":"stated","total_value":382241.6,"total_display":"382,241.60","total_whole":"382,242","shares_owned_after":4741.0,"shares_owned_after_display":"4,741","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-01","filed_date":"2018-03-05","scope":"insider"},{"id":6310338,"accession":"0001140361-18-004851","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-18-004851","line_url":"/filing/0001140361-18-004851#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2548.0,"shares_display":"2,548","price_per_share":26.6915,"price_display":"26.69","price_state":"stated","total_value":68009.942,"total_display":"68,009.94","total_whole":"68,010","shares_owned_after":4741.0,"shares_owned_after_display":"4,741","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-01","filed_date":"2018-02-02","scope":"insider"},{"id":6125813,"accession":"0001140361-18-000410","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-18-000410","line_url":"/filing/0001140361-18-000410#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":21.11,"price_display":"21.11","price_state":"stated","total_value":52775.0,"total_display":"52,775.00","total_whole":"52,775","shares_owned_after":7289.0,"shares_owned_after_display":"7,289","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-01-02","filed_date":"2018-01-03","scope":"insider"},{"id":4126818,"accession":"0001140361-17-045018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-17-045018","line_url":"/filing/0001140361-17-045018#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":20.58,"price_display":"20.58","price_state":"stated","total_value":51450.0,"total_display":"51,450.00","total_whole":"51,450","shares_owned_after":9789.0,"shares_owned_after_display":"9,789","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-01","filed_date":"2017-12-05","scope":"insider"},{"id":4190082,"accession":"0001140361-17-040975","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-040975","line_url":"/filing/0001140361-17-040975#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":50000.0,"total_display":"50,000.00","total_whole":"50,000","shares_owned_after":12126.0,"shares_owned_after_display":"12,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-01","filed_date":"2017-11-03","scope":"insider"},{"id":5074794,"accession":"0001140361-17-037554","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-037554","line_url":"/filing/0001140361-17-037554#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":18.1,"price_display":"18.10","price_state":"stated","total_value":45250.0,"total_display":"45,250.00","total_whole":"45,250","shares_owned_after":14626.0,"shares_owned_after_display":"14,626","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-02","filed_date":"2017-10-04","scope":"insider"},{"id":4702338,"accession":"0001140361-17-034349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-034349","line_url":"/filing/0001140361-17-034349#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":17.17,"price_display":"17.17","price_state":"stated","total_value":42925.0,"total_display":"42,925.00","total_whole":"42,925","shares_owned_after":17126.0,"shares_owned_after_display":"17,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-01","filed_date":"2017-09-05","scope":"insider"},{"id":4535069,"accession":"0001140361-17-031316","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-031316","line_url":"/filing/0001140361-17-031316#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":37500.0,"total_display":"37,500.00","total_whole":"37,500","shares_owned_after":19626.0,"shares_owned_after_display":"19,626","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-08-09","filed_date":"2017-08-11","scope":"insider"},{"id":5297784,"accession":"0001140361-17-027295","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-027295","line_url":"/filing/0001140361-17-027295#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001706863","owner_name":"RAY DEBANJAN","owner_display_name":"RAY DEBANJAN","owner_url":"/insider/0001706863","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":15.47,"price_display":"15.47","price_state":"stated","total_value":38675.0,"total_display":"38,675.00","total_whole":"38,675","shares_owned_after":22126.0,"shares_owned_after_display":"22,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":21,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":21,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":21},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Officer (Chief Financial Officer)","n_filings":18,"first_seen":"2017-07-06","last_seen":"2018-12-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001706863","retrieved_at":"2026-08-23T11:06:07+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}